2. Search Result
Search Result
Results for "

MMAF

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

3

Fluorescent Dye

3

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

2

Isotope-Labeled Compounds

1

Antibodies

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15579
    MMAF
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
    MMAF
  • HY-156225
    MMAF-OtBu

    		ADC Cytotoxin Cancer
    MMAF-OtBu (Example 2) is a modified MMAF (HY-15579 ). MMAF-OtBu can be used for synthesis of ADCs .
    MMAF-OtBu
  • HY-15579AS
    MMAF-d8 hydrochloride
    1 Publications Verification

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF-d8 (hydrochloride)e is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
    MMAF-d8 hydrochloride
  • HY-79253
    MMAF intermediate 1

    		ADC Cytotoxin Cancer
    MMAF intermediate 1 is an intermediate in the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF intermediate 1
  • HY-79254
    MMAF intermediate 2

    		ADC Cytotoxin Cancer
    MMAF intermediate 2 is an intermediate for the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF intermediate 2
  • HY-15579A
    MMAF hydrochloride
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F hydrochloride

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF hydrochloride
  • HY-15579B
    MMAF sodium
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F sodium

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF sodium
  • HY-W190923
    MMAF-methyl ester

    		ADC Cytotoxin Cancer
    MMAF-methyl ester is an ADC cytotoxin.
    MMAF-methyl ester
  • HY-15579G
    MMAF

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
    MMAF
  • HY-15579BG
    MMAF sodium

    Monomethylauristatin F sodium

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF sodium
  • HY-79256
    MMAF-OMe
    1 Publications Verification

    Monomethyl auristatin F methyl ester

    		 ADC Cytotoxin Cancer
    MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
    MMAF-OMe
  • HY-136287
    DBM-MMAF
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    DBM-MMAF is a agent-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody agent conjugate (ADC) .
    DBM-MMAF
  • HY-139326
    NHS-MMAF

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    NHS-MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent
    NHS-MMAF
  • HY-112786
    MC-Val-Cit-PAB-MMAF
    2 Publications Verification

    Vc-MMAF

    		 Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
    MC-Val-Cit-PAB-MMAF
  • HY-141594
    Modified MMAF

    		Microtubule/Tubulin Cancer
    Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer .
    Modified MMAF
  • HY-79255
    Fmoc-MMAF-OMe

    		ADC Cytotoxin Microtubule/Tubulin Cancer
    Fmoc-MMAF-OMe is an anticancer agent and tubulin polymerization inhibitor with an Fmoc protecting group. The active ingredient of Fmoc-MMAF-OMe, MMAF (HY-15579), is the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs) .
    Fmoc-MMAF-OMe
  • HY-145951
    Amidate-VC-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Amidate-VC-PAB-MMAF consists a cleavable ADC linker (Amidate-VC-PAB) and a potent tubulin polymerization inhibitor (MMAF). Amidate-VC-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). Amidate-VC-PAB-MMAF reduces off-target cytotoxicity of ADCs .
    Amidate-VC-PAB-MMAF
  • HY-133492
    DBCO-PEG4-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-MMAF
  • HY-101909
    Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-PAB-MMAF is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
    Val-Cit-PAB-MMAF
  • HY-44177
    Val-Cit-PAB-MMAF sodium

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-PAB-MMAF sodium is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
    Val-Cit-PAB-MMAF sodium
  • HY-128961
    MC-Alkyl-Hydrazine Modified MMAF

    		Drug-Linker Conjugates for ADC Cancer
    MC-Alkyl-Hydrazine Modified MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine .
    MC-Alkyl-Hydrazine Modified MMAF
  • HY-128968
    PEG4-aminooxy-MMAF

    Amberstatin; AS269

    		 Microtubule/Tubulin Drug-Linker Conjugates for ADC Inflammation/Immunology Cancer
    PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4 .
    PEG4-aminooxy-MMAF
  • HY-128711
    MAL-di-EG-Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) .
    MAL-di-EG-Val-Cit-PAB-MMAF
  • HY-141593
    Modified MMAF-C5-COOH

    		Drug-Linker Conjugates for ADC Cancer
    Modified MMAF-C5-COOH is a agent-linker conjugate for ADC .
    Modified MMAF-C5-COOH
  • HY-139325
    NHS-Modified MMAF

    		Drug-Linker Conjugates for ADC Others
    NHS-Modified MMAF (WO2012143499A2, intermediat 210) is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs) .
    NHS-Modified MMAF
  • HY-130990
    DBCO-PEG4-Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Val-Cit-PAB-MMAF
  • HY-164310
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF is a linker-drug conjugate, which is consisted of a click pair TCO, a spacer PEG, a cleavable linker Glu-Val-Cit, a PBAC group and a cytotoxin MMAF (HY-15579). TCO-PEG3-Glu-Val-Cit-PABC-MMAF can be used for synthesis of dual drug ADC .
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF
  • HY-153639
    Tyrosine-PEG4-aminooxy-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Tyrosine-PEG4-aminooxy-MMAF is a Linker-Payload conjugate that can be used to synthesize ARX788 .
    Tyrosine-PEG4-aminooxy-MMAF
  • HY-156758
    Mal-PEG8-Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PEG8-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAF contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162) .
    Mal-PEG8-Val-Cit-PAB-MMAF
  • HY-155744
    Acetylene-PEG3-MMAF-OMe

    LCB14-0536

    		 Drug-Linker Conjugates for ADC Others
    Acetylene-PEG3-MMAF-OMe (LCB14-0536) is a protein-active agent conjugate. Acetylene-PEG3-MMAF-OMe can be recognized by isoprenoid transferase . Acetylene-PEG3-MMAF-OMe is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-PEG3-MMAF-OMe
  • HY-153739
    N3-PEG3-VC-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    N3-PEG3-VC-PAB-MMAF
  • HY-W142140
    N-Methyl-DL-valine

    N-Methylvaline

    		 Amino Acid Derivatives Others
    N-Methyl-DL-valine is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
    N-Methyl-DL-valine
  • HY-W250408
    Fmoc-NMe-Val-Val-Dil-Dap-OH

    		Drug-Linker Conjugates for ADC Cancer
    Fmoc-NMe-Val-Val-Dil-Dap-OH is an intermediate for preparing drug-linker conjugate MC-MMAF, which can be used for synthesis of ADC molecule .
    Fmoc-NMe-Val-Val-Dil-Dap-OH
  • HY-157080
    Dibromomaleimide-C5-COOH

    DBM-C5-COOH

    		 ADC Linker Others
    Dibromomaleimide-C5-COOH (DBM-C5-COOH) is a bifunctional dibromomaleimide (DBM) linker. Dibromomaleimide-C5-COOH can be used to connect MMAF and to synthesize ADC .
    Dibromomaleimide-C5-COOH
  • HY-15583
    Auristatin F

    		ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F
  • HY-W142140A
    N-Methyl-DL-valine hydrochloride

    N-Methylvaline hydrochloride

    		 Others Cancer
    N-Methyl-DL-valine (N-Methylvaline) hydrochloride is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine hydrochloride involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
    N-Methyl-DL-valine hydrochloride
  • HY-15578G
    McMMAF

    Maleimidocaproyl monomethylauristatin F

    		 Drug-Linker Conjugates for ADC Cancer
    McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .
    McMMAF
  • HY-150233
    Cys-McMMAF

    		Microtubule/Tubulin Cancer
    Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .
    Cys-McMMAF
  • HY-15583S
    Auristatin F-d8

    		Isotope-Labeled Compounds ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F-d8
  • HY-164154
    ADC Control Human IgG1-vcMMAF

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
    ADC Control Human IgG1-vcMMAF
  • HY-15578
    McMMAF
    5 Publications Verification

    Maleimidocaproyl monomethylauristatin F

    		 Drug-Linker Conjugates for ADC Apoptosis Cancer
    McMMAF (Maleimidocaproyl monomethylauristatin F) is a maleimido-caproyl linker, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) with the protecting group maleimidocaproyl. McMMAF serves as an active molecule linker for ADC. McMMAF is non-cleavable and must be internalized and degraded within the cell to release cysteine-McMMAF as the active molecule. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth .
    McMMAF

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: